RecruitingNCT05880641

Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access

No-profit, Pilot, Observational, Multicentric, Prospective Study on the Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access to Facilitate Aortic Endovascular Repair. SHOCK-ACCESS STUDY.


Sponsor

EndoCore Lab s.r.l.

Enrollment

40 participants

Start Date

Jun 26, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The study will evaluate, in a controlled setting, the efficacy and safety of the intravascular lithotripsy using Shockwave™ M5+/L6 Peripheral Intravascular Lithotripsy Catheter to facilitate delivery of aortic large-bore devices in iliac calcified access.


Eligibility

Min Age: 18 Years

Inclusion Criteria9

  • Age ≥18 years old;
  • Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study;
  • Patient presenting with aortic disease indicated for endovascular treatment considered unfeasible based on severely calcified iliac access and outer diameter of the "ideal" aortic endograft at onset of the procedure (considering the main body and/or contralateral limb in case of iliac distal landing zone);
  • Patients presenting a ratio \> 0.2 between outer diameter of the aortic stent graft delivery system (OD-SG) and minimum lumen diameter (MLD); decision concerning SG will be taken balancing the lower profile on the market and the better graft fit for patient's anatomy;
  • Patients presenting calcium grade 3 or 4 accordingly to 360° coronary classification (grade 1 = 0-90°, grade 2 = 90°-180°; grade 3 = 180°-270°; grade 4 = 270°-360°);
  • Patients presenting a lesion length \> 20 mm, intended as the sum of all calcified iliac lesions between two endpoints, from the aortic bifurcation up to the proximal common femoral artery (CFA);
  • Patients eligible for treatment with Shockwave M5+ IVL device;
  • Patients presenting with aortic disease indicated for endovascular treatment associated or not to aorto-iliac occlusive disease (Rutherford classification score II - VI for chronic limb ischemia);
  • Patients compliant with the conduct of follow-up visits according to the timelines specified in the protocol.

Exclusion Criteria7

  • Bilateral Iliac Occlusion;
  • Urgent setting with presence of iliac thrombus (acute limb ischemia);
  • Any patient considered to be hemodynamically unstable at procedure onset;
  • Patients refusing treatment;
  • Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated;
  • Patients with a history of prior life-threatening contrast medium reaction;
  • Life expectancy of less than twelve months.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(6)

Azienda Ospedaliero Universitaria delle Marche

Ancona, Ancona, Italy

Sant'Orsola Hospital

Bologna, Emilia-Romagna, Italy

Fondazione PTV - Policlinico Tor Vergata

Rome, Lazio, Italy

Ospedale San Giovanni di Dio

Florence, Tuscany, Italy

Ospedale Santa Maria della Misericordia di Perugia

Perugia, Umbria, Italy

Azienda Ospedaliero-Universitaria di Padova

Padova, Veneto, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05880641


Related Trials